Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.77 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | MMP14 | P50281 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.34 |
| ▸ | FPR2 | P25090 | 2/20 | 0.33 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Delamanid SCHEMBL1046813 | 1.00 | PTGS1 (1.00) | PTGS1SLC6A2SLC6A4KCNH2CHRM1 | |
| Delamanid SCHEMBL57792 | 1.00 | PTGS1 (1.00) | PTGS1SLC6A2SLC6A4KCNH2CHRM1 | |
| SCHEMBL2097770 | 0.94 | PTGS1 (0.89) | PTGS1SLC6A2SLC6A4KCNH2CHRM1 | |
| SCHEMBL2097771 | 0.94 | PTGS1 (0.89) | PTGS1SLC6A2SLC6A4KCNH2CHRM1 | |
| SCHEMBL2091599 | 0.94 | PTGS1 (0.88) | PTGS1SLC6A2SLC6A4KCNH2CHRM1 | |
| SCHEMBL2091602 | 0.94 | PTGS1 (0.88) | PTGS1SLC6A2SLC6A4KCNH2CHRM1 | |
| SCHEMBL5540814 | 0.92 | PTGS1 (0.86) | PTGS1SLC6A2SLC6A4KCNH2CHRM1 | |
| SCHEMBL5544729 | 0.92 | PTGS1 (0.86) | PTGS1SLC6A2SLC6A4KCNH2CHRM1 | |
| SCHEMBL5540819 | 0.92 | PTGS1 (0.86) | PTGS1SLC6A2SLC6A4KCNH2CHRM1 | |
| SCHEMBL5542627 | 0.92 | KCNH2 (0.88) | PTGS1SLC6A2SLC6A4KCNH2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 818 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746883-A1 | COMBINATION PRODUCTS OF AT LEAST THREE ANTIBIOTICS COMPRISING BEDAQUILINE, PRETOMANID OR DELAMANID, AND A CYTOCHROME BC1 INHIBITOR, AND THEIR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | Janssen Pharmaceutica NV (BE) | 2026-05-27 | — | — | EP | claimed |
| CN-122017062-A | HPLC-MS/MS-based detection method for concentration of 8 two-wire antitubercular drugs | 杭州度安医学检验实验室有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-12616691-B2 | Use of fatty acid oxidation inhibitors as antimicrobials | WASHINGTON UNIVERSITY IN ST. LOUIS (US) | 2026-05-05 | — | — | US | claimed |
| EP-3790536-B1 | NANOCONTAINERS FOR TRANSPORTING NONPOLAR, LIPOPHILIC SUBSTANCES SUCH AS ANTIBIOTICS | KARLSRUHER INST TECHNOLOGIE (DE) | 2026-04-22 | — | — | EP | claimed |
| EP-4727950-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2026-04-22 | — | — | EP | claimed |
| US-12589127-B2 | Bacteriophages for treatment of tuberculosis | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2026-03-31 | — | — | US | claimed |
| US-12576118-B2 | Bacteriophages for the treatment of tuberculosis | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2026-03-17 | — | — | US | claimed |
| EP-4701639-A1 | MOLECULES TARGETING INFECTED TISSUES AND METHODS OF USE THEREOF | University of Tartu (EE) | 2026-03-04 | — | — | EP | claimed |
| US-20260048047-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | SCRIPPS RESEARCH INST (US) | 2026-02-19 | — | — | US | claimed |
| US-11254689-B2 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-02-22 | — | — | US | claimed |
| US-20220047561-A1 | SALTS OF CYCLOSERINE COMPOUNDS AND APPLICATIONS THEREOF | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2022-02-17 | — | — | US | claimed |
| US-8987304-B2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | claimed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | claimed |
| EP-2495563-A1 | DIAGNOSTIC AGENT FOR INFECTIOUS DISEASES | Fujifilm RI Pharma Co., Ltd. (JP) | 2012-09-05 | — | — | EP | claimed |
| US-20120219500-A1 | DIAGNOSTIC AGENT FOR INFECTIOUS DISEASES | FUJIFILM RI PHARMA CO., LTD. (JP) | 2012-08-30 | — | — | US | claimed |
| US-7943623-B2 | Pharmaceutical composition comprising 2,3-dihydro-6-nitroimidazo [2,1-B] oxazole derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-05-17 | — | — | US | claimed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | claimed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | claimed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576118-B2 | Bacteriophages for the treatment of tuberculosis | Q6ZSR9, TAF9, TBCD | PTGS1 4705/4885SLC6A2 1230/4885SLC6A4 3307/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | PTGS1 3838/4885SLC6A2 3396/4885SLC6A4 4191/4885 |
| US-20220047561-A1 | SALTS OF CYCLOSERINE COMPOUNDS AND APPLICATIONS THEREOF | TST, RIMKLA, PSPH | PTGS1 2635/4885SLC6A2 277/4885SLC6A4 156/4885 |
| US-12589127-B2 | Bacteriophages for treatment of tuberculosis | CHRM1, CHRM2, CHRND | PTGS1 3519/4885SLC6A2 859/4885SLC6A4 1876/4885 |
| US-20260048047-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | FNTB, PDE7A, TBL3 | PTGS1 2226/4885SLC6A2 3783/4885SLC6A4 4418/4885 |
| US-11254689-B2 | Compounds | SDHA, SDHB, FDPS | PTGS1 876/4885SLC6A2 1945/4885SLC6A4 3335/4885 |
| US-20120219500-A1 | DIAGNOSTIC AGENT FOR INFECTIOUS DISEASES | NISCH, CNDP2, MYADM | PTGS1 555/4885SLC6A2 3321/4885SLC6A4 2771/4885 |
| US-12616691-B2 | Use of fatty acid oxidation inhibitors as antimicrobials | CPT2, ACADM, ACOX3 | PTGS1 2025/4885SLC6A2 3321/4885SLC6A4 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.